An interventional study of Calmer in Premature Infant, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 26 Weeks to 30 Weeks. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.
Among the 139 studies in Premature Birth with a site in Canada, this one is the 90th largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2025, is one of 65 with no phase, reaches primary completion later than 22 of the 33 other live ones, and was the 132nd registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Women only
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages up to 29 wk
Michelle Baczynski · Sites in Canada, United States, Denmark
Ages 25 wk–29 wk
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 28 wk–32 wk
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 26 Weeks to 30 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 17 · Phase 4 5
First in 1998; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 80 across the 106 interventional studies, 144 across the 33 observational. Of the 78 that completed or were terminated, 9 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 139 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 9 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
5 of the studies in Premature Birth with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05114096McMaster UniversitySingle Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) | 2026-12-31 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07732257McGill University Health Centre/Research Institute of the McGill University Health CentreWireless MicroPremVitals Button Sensor in the NICU | 2027-01-30 |
| NCT05213806IWK Health CentreWithHolding Enteral Feeds Around Blood Transfusion (International) | 2027-03-31 |
| NCT07262385University of British ColumbiaCalmer Brains in Very Preterm Infants | 2027-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 139 studies in Premature Birth with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Very preterm infants in the neonatal intensive care unit (NICU) need lifesaving medical procedures which can be stressful and affect brain development. Calmer was invented to mimic key parts of parental holding (touch, heartbeat sounds and breathing motion) to help reduce stress if parents cannot be there to hold their infant. Using specialized brain scans done at full term, we will gather initial information in 22 infants born 3-4 months early to compare brain development in infants who receive Calmer at least 3 hours each day (+ regular NICU care) over 2-3 weeks with infants who have regular NICU care.
Very preterm infants (\< 32 weeks gestational age [GA]) experience developmentally unexpected, repeated stress as part of lifesaving care in the NICU during a period of considerable brain maturation and growth. Exposure to early-life stress alters brain maturation resulting in long-term changes in neurodevelopment. Parental skin-to-skin care (SSC) can mitigate stress; however, parents are not always available. Calmer, a patented, therapeutic medical device, was invented to simulate aspects of SSC (skin-like surface, breathing motion, heartbeat sounds) with rates of the latter two individualized for each infant. In a randomized trial, Calmer has been shown to stabilize brain blood flow during a single, routine blood test. Most recently, we found that very preterm infants who received Calmer treatment for 3 continuous weeks had 25% greater head growth compared to controls. However, we do not know if/how Calmer treatment affects brain development in very preterm infants.
Objectives: We will gather pilot data for a larger trial to examine differences in brain structural and functional development in very preterm infants who receive Calmer treatment for 2-3 consecutive weeks compared to controls.
Methods: 22 infants born 26-30 weeks GA admitted to BC Women's Hospital NICU will be randomized to either control (n=11) or treatment groups (n=11; Calmer for 2-3 continuous weeks, 3 hours/day minimum treatment). Infants from both groups will undergo feed and bundle MRI scans at term-equivalent age using high resolution volumetric, diffusion and resting-state functional MRI to explore group differences in whole-brain volumes and structural and functional connectivity. Images will be processed using existing quantitative neonatal imaging analysis pipelines in the Selvanathan and Weber labs at BC Children's Hospital Research Institute. Analyses will include: measures of trial feasibility and description of brain differences between groups.
Significance: Ultimately, Calmer may support healthy brain maturation optimizing the neurodevelopment of vulnerable infants in Canada and beyond.
Inclusion Criteria:
Exclusion Criteria: Infants who have
Infants in the Calmer group will have a Calmer\* placed and left in their incubators for a minimum of 2 and maximum of 3 weeks and will receive treatment for a minimum cumulative total of 3 hours/day (i.e. time can be discontinuous). Each day, after the infant's parent rests for 10 minutes, the research and/or bedside nurse will record the heart and respiratory rates for a 2-minute period (or taken by the caregiver themselves after training by research/NICU staff). The 1-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The values can be adjusted over the day as parents wish. \*Calmer, a patented, therapeutic bed that mimics key aspects of skin-to-skin care (SSC) to reduce stress in preterm infants. Calmer fits into NICU incubators and delivers 3 key SSC stimuli: touch, breathing motion, and heartbeat sounds (rates individualized to each infant based on their parents' HR/RR).
Device: Calmer
Infants in the Control group will receive standard NICU care, including parent SSC.
Calmer, a unique, patented, therapeutic bed that mimics key aspects of SSC that reduce stress in preterm infants. Calmer fits into NICU incubators and cribs, and delivers 3 key SSC stimuli: touch, breathing motion, and heartbeat sounds; the rates of the latter 2 stimuli are individualized to each infant based on their parents' breathing and heart rates. Calmer is designed to provide complementary care only when parents are not able to give SSC. It is not meant nor designed to replace human SSC, so will never be tested as such a replacement. Instead, Calmer was invented to enhance and optimize brain development in preterm infants by reducing stress during the NICU stay, when parents/caregivers are not available for SSC. Our ultimate goal is to enable use of Calmer from an infant's admission to discharge, only during those times when caregivers are not available.
Brain Volumes
Anatomical analysis: Anatomical images (T2w) will be manually inspected for quality control. Images with very poor tissue contrast or motion artefacts will be rejected. T2w images will be bias-field corrected using ANTs N4ITK. The images will then be skull-stripped and segmented using the dHCP anatomical pipeline to calculate total and sub-regional brain volumes.
Time frame: When each participant reaches 40 weeks post-conceptual age and return for their MRI scan
Brain Functional Connectivity
Resting state fMRI analysis: Fieldmaps will be generated using the dual-echo EPI and magnitude scan. The dHCP functional pipeline will be implemented to achieve distortion-correction and motion-correction, register the functional image to the corresponding T2w structural image, generate a transform matrix from functional space to the 40-week T2w template; and we will perform temporal high-pass filtering (150 s high-pass cutoff) and independent component analysis (ICA) denoising using ICA FIX. Scans with a mean FD \> 1 mm will be excluded. The dHCP functional pipeline will then be run on all subjects using the study-specific training file. Spatial smoothing of 5 mm will be applied using FSL's SUSAN and grand mean intensity normalization will be computed. Functional connectivity measures will be computed using the CONN toolbox.
Time frame: When each participant reaches 40 weeks post-conceptual age
Brain Fractional Anisotropy
Diffusion tensor imaging analysis: The dHCP neonatal dMRI data processing pipeline will be used to pre-process the diffusion weighted images. Briefly, opposite phase b0 images are used to estimate the off-resonance field that is then used in the simultaneous correction of motion artefacts, susceptibility-induced and eddy current distortions. Data will then be super-resolved and, after pre-processing is complete, local diffusion and microstructural models are fitted in every voxel and averaged to calculate mean fractional anisotropy.
Time frame: When participants reach term-equivalent age
Clinical weight measures
Weight: infant weight in kilograms captured when enrolled in the study (i.e. baseline T1) and end of experimental phase (2-3 weeks later; T2) We will use the weight measure to determine changes between baseline and the end of treatment.
Time frame: From the start of study treatment (or enrolment if Control group) to 2-3 weeks later, at the end of intervention exposure.
Head growth measures
Head circumference: infant head circumference in centimetres (occipito-frontal circumference) captured when enrolled in the study (i.e. baseline T1) and end of experimental phase (2-3 weeks later; T2). We will use the head circumference measures to determine changes between baseline and the end of treatment.
Time frame: From the start of study treatment (or enrolment if Control group) to 2-3 weeks later, at the end of intervention exposure.
Trial feasibility
Consent rate: overall average consent rate of infants/month
Time frame: 2 years from the start of the study
Trial feasibility
Protocol delivery: % of on/off protocol infants
Time frame: 2 years from the start of the study
Trial feasibility
Outcome measures: % of infants with complete primary outcome data
Time frame: 2 years from the start of the study
Trial feasibility
Rate/nature of safety issues
Time frame: 2 years from the start of the study
Plan to share: Yes — As part of this study, participants' de-identified research data may be shared in a public database when the research is published. Sharing this deidentified data helps make research more transparent and allows others to double-check the results. It also means that other researchers can use the data for different studies in the future, beyond the scope of this current study. The exact details have not been decided yet.
Supporting information: Study protocol, Clinical study report, Analytic code
Time frame: When the research findings are published.
Access criteria: We have not decided on these details.
Data sharing details ↗ · notcurrentlyavailable.ca
Start is estimated for Dec 2025; primary completion for Apr 2027, 16 months later.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 16 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →